The primary objective of the study is the evaluation of sustained response rate after discontinuation of treatment with TPO-RAs, Eltrombopag and Romiplostim, in persistent or chronic pITP patients who failed one or more therapy lines, splenectomy included. Increasing evidence exists in the literature on the persistent response after TPO-RAs discontinuation.

Italy

https://clinicaltrials.gov/ct2/show/NCT02298075?recrs=a&cond=ITP&draw=1&rank=23

Recruiting